AstraZeneca to invest more than RM500mil in Malaysia over five years

Strength in numbers: AstraZeneca is making available preclinical data from more than 50 of its medicines to help accelerate the hunt for synergistic tumour-fighting drug combinations.

KUALA LUMPUR: Biopharmaceutical company AstraZeneca will invest more than RM500mil (US$125mil) in Malaysia over the next five years for a new headquarters and to roll out new robotic and cognitive technology 

It said on Tuesday the investment will include a new AstraZeneca Malaysia headquarters in Nucleus Tower, Mutiara Damansara to house its local and global business operations across a wide variety of functions, such as finance and procurement leadership for the region.

The company said the investment demonstrated its commitment towards patients, innovation and talent development in the country and rolling out the new technology as it seeks to improve  efficiency and drive productivity across its global operations. 

“In addition, a new global business services hub will be equipped with cutting-edge robotic technology and automation to support financial, accounting and business services for AstraZeneca operations in the Asia Pacific region,” it said. 

The hub is one of AstraZeneca’s three shared services hubs globally, including in Costa Rica and Poland.

AstraZeneca is planning a close collaboration with partners to explore digital transformation in the management of cardiovascular diseases, respiratory diseases and cancer in Malaysia.